Skip to content
    NTRA
    Earnings call· Mar 2025(Q1 FY25)

    Natera Q1 FY25 earnings call NTRA

    May 8, 2025 Source

    Executive summary

    Natera Q1 FY25 — Record Volumes, Strong Margins, and Raised Outlook

    Natera delivered a robust Q1 FY25, marked by record test volumes and significant revenue growth, driven by strong performance across all segments, particularly Signatera. The company is strategically investing in oncology, with numerous clinical data readouts expected to further expand Signatera's utility and market penetration. Continued gross margin expansion and cash generation underscore the company's operational efficiency and long-term growth potential.

    Highlights

    6
    • Generated $502 million in revenue, representing approximately 37% year-over-year growth.

    • Processed 855,000 units in the quarter, including a record volume quarter for Signatera.

    • Signatera clinical volumes grew 52% year-on-year and increased by roughly 16,500 units sequentially.

    • Achieved gross margins of 63%, with underlying gross margin improving 110 basis points sequentially to 60.4%.

    • Generated $23 million in cash flow, while doubling down on growth investments.

    • Substantially raised full-year revenue guidance by $70 million at the midpoint to a range of $1.94 billion to $2.02 billion.

    Guidance & targets

    10
    CategoryTargetConfidence
    Full-year Revenue
    $1.94B-$2.02B
    high materiality
    High
    Full-year Gross Margin
    60%-64%
    medium materiality
    High
    Cash Flow
    Cash flow breakeven
    medium materiality
    High
    Signatera Annual Revenue Potential
    More than $5 billion annually
    high materiality
    High
    Signatera ASP
    Above $2,000 per test
    high materiality
    Medium
    Gross Margin Target
    Above 70%
    medium materiality
    Medium
    Japan PMDA Approval (Signatera)
    Approved
    medium materiality
    Medium
    Japan Reimbursement (Signatera)
    Impact top line
    medium materiality
    Medium
    PROSEE Study Readout
    Readout
    medium materiality
    High
    FIND Study First Patient In
    First patient in
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Women's Health
    Had an outstanding quarter, extending strong 2024 growth. NIPT and carrier screening are both growing nicely.
    Sequential unit growth: 40,000+ units (Q1 vs Q4)Annual unit growth: hundreds of thousands of units (FY24 YoY, ex-Invitae)
    40,000+ units sequential growth
    Organ Health
    Very strong growth, with significant interest in donor-derived cell-free DNA and germline tests.
    50%+ year-on-year growth
    Oncology (Signatera)
    Achieved a record volume quarter, driven by strong clinical utility and broad adoption among oncologists. ASPs moved above $1,100 due to Medicare Advantage reimbursement.
    Sequential unit growth: 16,500 units (Q1 vs Q4)Oncologists ordering: >45% in the US (last quarter)Average Selling Price (ASP): >$1,100 (in Q1)
    52% year-on-year growth16,500 units sequential growth

    Operational metrics

    18
    Total Units Processed
    855,0008% sequential increase over Q4 2024
    Q1 FY25

    Strong growth across the business, one of the best quarters ever.

    Underlying Gross Margin
    60.4%110 bps sequential improvement from Q4 2024
    Q1 FY25

    Excluding $34 million in true-ups, showing improvement from ASP trends and COGS efficiencies.

    Cash Flow Generated
    $23M
    Q1 FY25

    Generated cash even while increasing growth investments.

    Cash and Investments Balance
    Nearly $1B
    Q1 FY25

    Maintained a pristine balance sheet with no debt outside of a line of credit.

    Signatera Average Selling Price (ASP)
    Above $1,100
    Q1 FY25

    Driven primarily by continued execution on securing Medicare Advantage reimbursement.

    Sarcoma Study Recurrence Sensitivity
    89%
    Q1 FY25

    Overall recurrence sensitivity in the Stanford-led sarcoma study.

    Sarcoma Study Specificity
    100%
    Q1 FY25

    Specificity in the Stanford-led sarcoma study.

    Sarcoma Study Leiomyosarcoma Sensitivity
    93%
    Q1 FY25

    Sensitivity for the leiomyosarcoma subtype in the Stanford-led sarcoma study.

    Signatera Genome Assay Sensitivity
    90%-100%
    Q1 FY25

    Clinical data with Signatera Genome across hundreds of patients and thousands of plasma samples.

    Signatera Genome Assay Specificity
    Approaching 100%
    Q1 FY25

    Clinical data with Signatera Genome, showing high specificity maintained with improved sensitivity.

    Sarcoma New Diagnoses
    17,000
    Per year

    Sarcoma is an important indication with significant unmet needs.

    Oncologists Ordering Signatera
    Over 45%
    Last quarter

    Indicates broad adoption and market penetration for Signatera.

    22q Tests
    1 million
    This year

    Estimated number of 22q tests performed this year, currently not reimbursed.

    22q CPT Code Price
    $750
    Current

    The CPT code for 22q is priced around this amount on the CMS fee schedule.

    Signatera Genome Detection Frequency
    As low as a single tumor copy per million
    Current

    Leverages patented multiplex PCR technology and targeted deep sequencing.

    Signatera Exome Detection Frequency
    Low single-digit parts per million
    Current

    Regularly detects in the ultrasensitive range.

    Prospera DQS False Positives Reduction
    37%
    Current

    Reduction in false positives when using Prospera with DQS compared to donor fraction alone.

    Prospera Outperformance vs. Biopsy
    Threefold
    Current

    Prospera outperformed serial biopsy in predicting graft dysfunction in heart transplant patients.

    Industry KPIs

    2
    MetricValueDetails
    Launch access metricsOver 45%%
    Peak long term sales guidanceMore than $5B annuallyUSD

    Deals & partnerships

    2
    GenentechCollaboration on the IMvigor011 trial for muscle-invasive bladder cancer.

    Genentech is running the IMvigor011 trial, with Natera providing Signatera testing. This trial has the potential to lead to the first companion diagnostic label through FDA for Signatera.

    Stanford UniversityCollaboration on a sarcoma study for ctDNA analysis.

    Stanford-led study presented at the Society of Surgical Oncology Conference, showing excellent results for serial Signatera in sarcoma patients. This was the largest sarcoma study in ctDNA analysis to date.

    What to watch in Q2 FY25

    5

    IMvigor011 Trial Readout

    Midyear
    CurrentTrial ongoing
    TargetReadout of results

    Why it matters

    This trial has the potential to move the needle in GU with muscle-invasive bladder cancer and could lead to Signatera's first companion diagnostic label through FDA.

    We're looking forward to the readout of the IMvigor011 trial, which were -- we've done in partnership with Genentech. That's their trial, so they're going to read that out, but we do expect that to be midyear.

    Q&A highlights

    5

    What drove the strong sequential Signatera volume growth, and is it sustainable for the rest of the year?

    The strong growth is attributed to the test's data, performance, clinical utility, large commercial presence, and user experience (quick TAT, EMR, mobile phlebotomy). While pleased, the company is not changing its previous sequential growth expectation of 10,000-12,000 units, implying the record pace might not be sustained but growth will continue.

    We're just seeing that the data that we generated, the performance of the test, the very strong clinical utility is resonating with physicians. And that, combined with the large commercial presence that we have plus the very significant scale and user experience focus that we have, whether it's quick turnaround time, EMR capability, mobile phlebotomy, all of those things are working and the volume is increasing.

    asked by Dan Brennan · answered by Steve Chapman

    3 min read7 chapters

    Detailed Narrative

    01

    Record Q1 Performance and Raised Full-Year Outlook

    Natera reported a strong Q1 FY25, achieving $502 million in revenue, a 37% increase year-over-year, and processing a record 855,000 units. This performance was driven by outstanding volume growth across all segments, including a significant sequential step-up in Women's Health and a record quarter for Signatera. Consequently, the company raised its full-year revenue guidance by $70 million at the midpoint, now expecting revenues between $1.94 billion and $2.02 billion, implying approximately 26% growth ex-true-up📎s.

    02

    Oncology Pipeline and Data Leadership

    The company highlighted its robust oncology pipeline and extensive data generation efforts for Signatera. Upcoming presentations at ESMO Breast and ASCO include data from the ISPY-2 trial in breast cancer, the DARE randomized study, and the largest sarcoma study to date, demonstrating Signatera's utility in various cancer types and settings. These studies, many initiated years ago, reinforce Natera's leadership in MRD and are expected to further expand clinical utility and adoption.

    03

    Gross Margin Expansion and ASP Improvement

    Natera continued to demonstrate strong gross margin expansion, reaching 63% in Q1, with underlying gross margin improving 110 basis points sequentially to 60.4%. This improvement was attributed to increased average selling prices (ASPs) across Women's Health, Organ Health, and Oncology, alongside scale efficiencies from robust volume growth. The company maintains a long-term goal of achieving gross margins above 70%, driven by further ASP increases from guideline changes and commercial payer reimbursement.

    04

    Strategic Investments for Future Growth

    Despite generating $23 million in cash flow during the quarter, Natera emphasized its commitment to strategic investments, particularly in Signatera. Recognizing Signatera's potential to generate over $5 billion in annual revenue, the company is funding high-return-on-investment initiatives in commercial operations, clinical trials, and product improvements. This investment strategy aims to maximize out-year revenue growth while maintaining cash flow breakeven for the full year.

    05

    Organ Health Advancements with Prospera

    In Organ Health, Natera reported strong year-on-year growth exceeding 50%. The company highlighted positive readouts from the prospective DEFINE study in heart transplantation, demonstrating Prospera's ability to predict clinical outcomes and outperform biopsy in predicting graft dysfunction. The study also validated the novel Donor Quantity Score (DQS), which, when combined with donor fraction, delivered improved sensitivity and specificity, including a 37% reduction in false positives.

    06

    Colorectal Cancer Screening Progress

    Natera provided updates on its colorectal cancer screening initiatives. The PROSEE study has completed enrollment of over 3,000 patients, with results expected by the end of the year. Additionally, the FDA-enabling FIND study is on track to enroll its first patient this month, mirroring the design of PROSEE to ensure reliable data for regulatory submission. These efforts underscore the company's commitment to expanding into the significant colorectal cancer screening market.

    07

    Global Expansion and Market Penetration

    The company is making progress on global expansion, with the Signatera regulatory submission in Japan currently under review by the PMDA, expected to be approved by late 2025 or early 2026. This would be followed by a reimbursement submission, potentially impacting the top line by late 2026. Domestically, Natera noted that over 45% of oncologists in the U.S. ordered a Signatera test last quarter, indicating broad, albeit early-stage, market penetration.

    AI-generated summary of the company’s earnings call. Not investment advice.